Base Editing: Top Companies, Startups & Research

Beam Therapeutics and Life Edit Therapeutics Inc. are among the companies working on base editing. Beam develops therapeutic programs, including its BEAM-302 candidate for alpha-1 antitrypsin deficiency, while Life Edit describes a platform with RNA-guided nucleases and base editors. The available company information is more detailed for these organizations than for most other commercial players.

Harvard University, the Chinese Academy of Sciences CAS and the Chinese Academy of Agricultural Sciences are prominent research organizations in the field. Their recent work includes in vivo disease-model editing, AlphaFold3-based contact modelling, and plant editing with Cas12i3 variants. Harvard University has 124 documents in the defined window, and the Chinese Academy of Sciences CAS has 90.

The recorded grant data show $31,408,388 across 23 grants since 2020. This is a measure of grants matched to the topic, not a comprehensive total of all public or private investment in base editing. The available funding-round entries include items that may not be specific to the technology, so they should not be treated as a clean industry investment total.

Beam Therapeutics leads the listed patent holders with 49 patents, followed by Harvard University with 27 and The Broad Institute Inc. with 23. Other listed holders include Intellia Therapeutics, Shandong Shunfeng Biotechnology Co. and Life Edit Therapeutics Inc. Patent counts indicate recorded holdings associated with base editing, not the full scope or legal strength of each organization's intellectual property.

No: patent activity declined 47.0% in the last 12 months compared with the previous 12 months. There were 381 patents in the defined 24-month window. Publication activity moved in the opposite direction, rising 30.6% in the last 12 months. These different trends suggest that research output remains active even as the recorded pace of patenting has slowed.

Base editing is in early clinical translation: the data include 30 clinical-trial records, and an August 2026 Phase I/II protocol evaluates LNP.UCD.ABE for urea-cycle disorders. Research also reports in vivo results in animal models, including disease rescue and lipid reduction. Clinical maturity remains limited by delivery, off-target assessment and the need to show safety and durable benefit in people.

Recent developments include Fudan University's transformer base editor, reported in September 2026 to improve editing efficiency while reducing off-target mutations, and hybrid guide RNAs that improved the specificity and efficiency of in vivo adenine editing. In August 2026, a Phase I/II protocol for LNP.UCD.ABE added a clinical direction for base editing in urea-cycle disorders.

The main approaches are adenine editors, cytosine editors, transversion editors, RNA editors and editor optimization. Adenine and cytosine editors make different transition substitutions in DNA; transversion editors aim for other substitution types. RNA editors change transcripts rather than genomic DNA, while optimization work improves properties such as precision, efficiency or target range. Each approach has distinct targeting and unwanted-edit trade-offs.

The United States leads the recorded activity with 4,803 documents, followed by China with 2,377 and the United Kingdom with 1,135. Germany and India are also among the leading countries in the data. Activity is international: recent examples include editor engineering and crop applications from research groups in China, South Korea and the United States.

Applications include rare genetic diseases, blood disorders, cardiovascular and metabolic disease, cancer and cell therapy, agriculture and animal breeding, and functional genomics. The data show substantial research activity in cancer and cell therapy, rare disease and blood disorders. Recent studies also report in vivo editing for phenylketonuria, progeria and lipid regulation, as well as editing methods for plant improvement.